Sinopharm Group Co. Ltd (X2S) — Capital Reinvestment Ratio
Latest as of December 2022:
0.01x
Sinopharm Group Co. Ltd (X2S) has a Capital Reinvestment Ratio of 0.01x as of December 2022, meaning it reinvests 0% of its operating cash flow (€52.39 Billion) in capital expenditures (€654.69 Million). See cash generation quality of Sinopharm Group Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.01x
Capex / Operating Cash Flow
Operating Cash Flow
€52.39 Billion
EUR
Capital Expenditures
€654.69 Million
EUR
Data as of
Dec 2022
Most recent filing
Sinopharm Group Co. Ltd Capital Reinvestment Ratio (2013–2025)
This chart tracks Sinopharm Group Co. Ltd's Capital Reinvestment Ratio across 13 annual periods.
Annual Capital Reinvestment Ratio for Sinopharm Group Co. Ltd (2013–2025)
Year-by-year Capital Reinvestment Ratio for Sinopharm Group Co. Ltd from 2013 to 2025. For live market cap and broader valuation context, see Sinopharm Group Co. Ltd (X2S) total market value.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | €14.14 Billion | €1.62 Billion | ▼ -32.9% |
| 2024 | 0.17x | €11.55 Billion | €1.97 Billion | ▲ +25.3% |
| 2023 | 0.14x | €17.17 Billion | €2.34 Billion | ▲ +34.1% |
| 2022 | 0.10x | €20.96 Billion | €2.13 Billion | ▼ -54.5% |
| 2021 | 0.22x | €9.31 Billion | €2.07 Billion | ▲ +31.0% |
| 2020 | 0.17x | €11.15 Billion | €1.90 Billion | ▲ +44.8% |
| 2019 | 0.12x | €18.78 Billion | €2.21 Billion | ▼ -86.8% |
| 2018 | 0.89x | €3.65 Billion | €3.24 Billion | ▲ +34.2% |
| 2017 | 0.66x | €3.21 Billion | €2.12 Billion | ▲ +348.6% |
| 2016 | 0.15x | €9.26 Billion | €1.36 Billion | ▲ +93.6% |
| 2015 | 0.08x | €13.41 Billion | €1.02 Billion | ▼ -70.8% |
| 2014 | 0.26x | €5.56 Billion | €1.45 Billion | ▲ +14.2% |
| 2013 | 0.23x | €4.94 Billion | €1.13 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow